{"title":"Is There Such a Thing as Tangible Heritage?","authors":"Jeremy C. Wells","doi":"10.1353/fmj.2018.0025","DOIUrl":"https://doi.org/10.1353/fmj.2018.0025","url":null,"abstract":"Abstract:University of Maryland professor Jeremy C. Wells, contemplates the nature of cultural heritage, suggesting that heritage is innately intangible. The concept of intangible heritage, then, is tautological, akin to saying \"intangible intangible.\" Additionally, notes Wells, tangible heritage, the places and objects preservationists work to protect, is an equally absurd notion that assumes a \"tangible intangible.\"","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"22 1","pages":"15 - 24"},"PeriodicalIF":0.0,"publicationDate":"2020-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87298229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Shared Spaces, Invisible Imprints: Intersections of Latinx and African American Intangible Heritage","authors":"Sehila Mota Casper, Lawana Holland-Moore","doi":"10.1353/fmj.2018.0026","DOIUrl":"https://doi.org/10.1353/fmj.2018.0026","url":null,"abstract":"Abstract:Historic Preservation staff at the National Trust for Historic Preservation, Sehila Mota Casper and Lawana Holland-Moore, explore how the experience and cultural heritage of African American and Latinx communities often overlap creating areas of common intangible heritage. By empowering communities of color to preserve both the tangible and intangible aspects of heritage and identity, historic preservationists can foster a greater understanding of the histories that connect individuals and communities to one another.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"12 1","pages":"25 - 33"},"PeriodicalIF":0.0,"publicationDate":"2020-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85215476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vestiges of Vietnam: Uncovering the Hidden Heritage of Virginia's Little Saigon","authors":"K. O'Connell","doi":"10.1353/fmj.2018.0027","DOIUrl":"https://doi.org/10.1353/fmj.2018.0027","url":null,"abstract":"Abstract:Journalist and daughter of a Vietnamese immigrant, Kim O'Connell explores the disappearance of places associated with Vietnamese immigrants to the Clarendon neighborhood of Arlington, Virginia, during the years following the end of the Vietnam War. As Vietnamese American populations were priced out of Arlington and moved deeper into the Washington, D.C., suburbs, the shops and restaurants associated with the \"Little Saigon\" commercial district in Clarendon vanished, but new efforts to preserve the intangible are ensuring the history of Vietnamese immigrants to the United Sates is represented as part of the broader historical narrative.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"23 1","pages":"34 - 43"},"PeriodicalIF":0.0,"publicationDate":"2020-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75398162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Working-class Intangible Heritage from the Pennsylvania Coal Fields","authors":"Camille Westmont","doi":"10.1353/fmj.2018.0021","DOIUrl":"https://doi.org/10.1353/fmj.2018.0021","url":null,"abstract":"Abstract:V. Camille Westmont, doctoral candidate in anthropology at the University of Maryland, explores northeastern Pennsylvania's coal mining region and the intangible heritage of the places that once were coal mine company towns. Miners and their families lived in poverty, and the coal companies controlled most aspects of their lives, from housing and food to commercial goods. The intangible heritage of the resource economy these families developed to survive is now all that is left of the coal mining era, with company towns now indistinguishable from other rural and suburban areas.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"9 1 1","pages":"54 - 63"},"PeriodicalIF":0.0,"publicationDate":"2020-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78643625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beta-3 Receptor Agonists","authors":"E. Bachus, P. Ponikowski","doi":"10.17987/icfj.v18i0.615","DOIUrl":"https://doi.org/10.17987/icfj.v18i0.615","url":null,"abstract":"Beta-3 adrenergic receptors (β3-AR) have a more widespread tissue distribution in the human body as compared to beta1- and beta2 (β1/2)-adrenergic receptors, including in the bladder, brain, adipose tissue and cardiovascular system. Thus, β3- AR are potential drug targets for a wide range of therapeutic areas, both cardiovascular and non-cardiovascular including overactive bladder (OAB), depression, metabolic syndrome, obesity and heart failure (HF). β3-AR agonists that are selective to the β3-AR include CL 316,243, amibegron (SR58611A), mirabegron (YM-178) and vibegron (RVT-901). However, in HF, study results regarding a possible inotropic effect of β3-AR agonists remain equivocal and some authors report a negative inotropic effect in HF and β3-AR antagonists are also under study.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"279 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78465289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"If Channel Inhibition - Ivabradine for the Treatment of Heart Failure","authors":"G. Rosano, C. Vitale","doi":"10.17987/icfj.v17i0.599","DOIUrl":"https://doi.org/10.17987/icfj.v17i0.599","url":null,"abstract":"The novel first-in-class If channel antagonist, Ivabradine, is effective in improving clinical outcomes and functional capacity, in patients with HF, as well as demonstrating useful anti-anginal and protective anti-ischaemic effects. It can help improve heart rate control and can be usefully co-administered with beta blockers on HFrEF patients with residually elevated resting sinus rhythm heart rate. We review the clinical trial evidence for the benefits of Ivabradine in the treatment of heart failure.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81439509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genes, Cells, and MiRNAs","authors":"E. Gara, M. Lainščak","doi":"10.17987/icfj.v18i0.617","DOIUrl":"https://doi.org/10.17987/icfj.v18i0.617","url":null,"abstract":"Novel methods to treat HF include gene, cell and microRNA delivery. There have been few gene therapy trials in HF. The CUPID I and II trials with AAV1.SERCA2a showed unconvincing results. The STOP-HF trial using direct intra-myocardial injection of a non-integrating plasmid vector carrying stromal cell-derived factor-1 showed no clinical effects and the AC6 gene transfer trial used IC infusion of escalating doses of Ad5.hAC6 was similarly negative. Despite high hopes stem cell trials to date in HF have not shown convincing clinical benefits. More recent clinical trials in this area have investigated the injection of cell stimulating paracrine factors (peptides, small molecules, hormone-like molecules) without actual cell delivery. Micro-RNA’s (miRNAs) are small non-coding RNA strands, comprising 19-25 nucleotides, that have a distinct signalling role and a various patterns of expression in ischaemic myocardium, hypertrophy, cardiomyopathies, and overt HF. They act at the post-transcriptional regulation level. Numerous novel miRNAs have been discovered, and their in-depth role has been characterised. miRNAs can serve as therapeutic substances or therapeutic targets in a range of cardiovascular diseases. Clinical trials are likely in the near future.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89388097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mineralocorticoid Receptor Antagonists","authors":"I. Spoletini, G. Rosano","doi":"10.17987/icfj.v17i0.603","DOIUrl":"https://doi.org/10.17987/icfj.v17i0.603","url":null,"abstract":"The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is well-recognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to reduce mortality in HFrEF. In patients with HFpEF, the TOPCAT trial found no significant benefits of spironolactone on cardiovascular outcomes. In order to overcome the limitations of existing steroidal MRAs, novel MRAs have been recently developed, finerenone and PF-03882845.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84998012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Scientific Targets: the Myocardium, the Vasculature and the Body’s Response to Heart Failure","authors":"R. Vidal-Pérez, E. Jankowska","doi":"10.17987/icfj.v17i0.593","DOIUrl":"https://doi.org/10.17987/icfj.v17i0.593","url":null,"abstract":"Heart failure (HF) is a common but complex clinical syndrome associated with a reduced ability of a heart to pump and/or fill with blood. We now appreciate the more complex picture involving metabolic derangements, changes in foetal gene expression and abnormalities in the periphery as forming part of the HF syndrome. Therapeutic targets include the failing myocardium, the vasculature and peripheral mechanisms. The pathophysiology of HF is currently being intensively investigated, with the identification of new relevant mechanisms, some of them emerging as potential therapeutic targets.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"30 19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83178803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Modulation of Cardiac Metabolism in Heart Failure","authors":"G. Rosano, A. Coats","doi":"10.17987/icfj.v17i0.597","DOIUrl":"https://doi.org/10.17987/icfj.v17i0.597","url":null,"abstract":"Heart failure is associated with altered cardiac metabolism, in part, due to maladaptive mechanisms, in part secondary to comorbidities such as diabetes and ischaemic heart disease. The metabolic derangements taking place in heart failure are not limited to the cardiac myocytes, but extend to skeletal muscles and the vasculature causing changes that contribute to the worsening of exercise capacity. Modulation of cardiac metabolism with partial inhibition of free fatty acid oxidation has been shown to be beneficial in patients with heart failure. At the present, the bulk of evidence for this class of drugs comes from Trimetazidine. Newer compounds partially inhibiting free fatty acid oxidation or facilitating the electron transport on the mitochondrial cristae are in early phase of their clinical development.","PeriodicalId":32119,"journal":{"name":"International Cardiovascular Forum Journal","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88328710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}